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Abstract Since the mid-1980s the number of cases of TB notified within the U.K. has continued to rise although the
contribution of HIV to this rise remains unclear. A12-month prospective cohort study was conducted at chest and HIV
clinics in four hospitals in Lambeth, Southwark and Lewisham (LSL), an area of South London, to determine the propor-
tion of patientswith culture-provenTB infectedwith HIV.Secondary aimswere to determine the proportion of patients
withTB and undiagnosed HIVat first presentation to chest clinics, to determine the proportion of patients presenting
withTB as an AIDS defining illness (ADI) and to identify risk factors for co-infection withTB and HIV. In chest clinics,
demographic data and left-over blood frompatients aged16 or over with culture-provenTBwas collected, anonymised
and HIV tested. In HIV clinics, demographic data on patients withTB already known to be HIV seropositive were also
obtained.Twenty-one patients (13%,95% CIF8^19%) of159 with culture-provenTBwere infectedwith HIV.Four (3%)
of 133 patients at first presentation to chest clinics had undiagnosed HIV; two were subsequently diagnosed.Of the 21
patientswithTB and HIV, nine (43%) presentedwithTB as an ADI.PatientswithTB and HIV were significantlymorelikely
to be aged between 35 and 55 years compared to HIV seronegative patients [12/21 (57%) vs. 38/138 (28%), P=0.006].
None ofthepatients fromthe Indian SubcontinentwereHIV seropositive [0/21vs.25/138 (18%),P=0.047].Atthepresent
time, universal HIV testing of patients with culture-provenTB in chest clinics within the U.K. is unlikely to significantly
reduce the numberof patientswithundiagnosed HIV.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp.//www.sciencedirect.com
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During themid-1980s, the decline in noti¢ed cases of tu-
berculosis (TB) within the U.K. was reversed and the
highest increases were noted in London and inner city
areas. In 1998, over 6000 new cases of TB were noti¢ed
and in London noti¢cation rates were three times the na-
tional average.Nearly 50%of allnewcaseswere diagnosed
in ethnic minority groups including recently arrived immi-
grants fromareas of highHIVprevalence (1). AlthoughHIV
increases the likelihood that infectionwill progress to dis-
ease (2),HIVwas not thought tohave signi¢cantly contrib-
uted to the U.K. rise in noti¢ed cases of TB (3,4).
Guy’s, St Thomas’,King’sCollege and LewishamHospi-
tals serve the South London communities of Lambeth,
Southwark and Lewisham (LSL). Approximately onemil-Received 8 May 2002, accepted in revised form 25 June 2002
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8869 2009lion people livewithin these communities and 25% are from
ethnic minority groups compared to an average of 6% for
England and Wales. In 1998, approximately 500 new cases
of HIVwere diagnosed andnoti¢ed in LSL and TB rates ex-
ceeded 30/100 000, the seventh highest in theU.K. (1).
The primary aim of this study was to determine the
proportion of patients with culture-proven TB also in-
fected with HIV in LSL.The secondary aims were to de-
termine the proportion of patients with culture-proven
TB andundiagnosedHIVattending chest clinics, to deter-
mine the proportions of patients withTB and HIV pre-
senting withTB as an AIDS de¢ning illness (ADI) and to
identify risk factors forTB and HIV co-infection.
METHODS
Between December1999 and November 2000, patients
aged16 years or older with newlydiagnosed or recurrent
culture-provenTB were recruited into this prospective
cohort study. A research nurse collected demographic
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nicity and year of arrival in theU.K.) onpatientswith sus-
pected TB attending chest clinics. Following blood tests
taken for other purposes, leftover serum of suspected
TB patients was stored at 201C.When M. tuberculosis
was cultured from clinical specimens, serum samples
were allocated a random number and unlinked to all
identi¢ers before HIV testing. All outpatient chest
clinics displayed a Department of Health poster explain-
ing, in 14 di¡erent languages, that left-over blood could
be anonymised and HIV tested. A lea£et was available
to reinforce this message. Patients could have refused to
allow their serum to be tested anonymously. Eligible
sampleswere tested at the end of the study after all data
entry had been checked. Ethical approval was obtained
from the ethics committees of Guy’s and St Thomas’ Hos-
pital, King’s College Hospital and LewishamHospital.
Demographic data on patientswithTB, alreadyknown
to be HIV seropositive and attending HIV clinics, were
obtained by reference to notes and consultation with
HIV physicians. The proportion of patients presenting
withTB as an ADI was established.
Mycobacterial cultures
All pulmonary and extrapulmonary samples were aura-
mine stained and subcultured onto Lowenstein^Jensen
and Middlebrook’s media. All smear positive and extra-
pulmonary sampleswere directly inoculated intoKirsch-
ner’s broth and the automated liquid MB/BacT system
(OrganonTeknika,Cambridge,U.K.) to expedite the time
to culture. Speciation was determined by biochemical
testing and DNA hybridisation (Accuprobe) and antimi-
crobial susceptibility performed using the resistance ra-
tio method on Lowenstein^Jensen medium or the
radiometric BACTEC 460 method (5).
HIV testing
Fiftymicrolitres of patient serumwerepooled inbatches
of10 and each pool tested for HIVantibodies (Micropar-
ticle enzyme immunoassay (MEIA), Abbott Axsym sys-
tem). Previous studies have demonstrated that pooling
and10-fold dilution of serumdoes not signi¢cantly lower
the sensitivity of HIV testing (6). Samples in HIVreactive
pools were re-tested individually.Reactive samples were
con¢rmed by a Wellcozyme HIV-1 speci¢c competitive
ELISA (Murex Biotech Ltd, Dartford,U.K.) and an HIV-1
speci¢c gel particle agglutination assay (Serodia, Fujirei-
bo Inc, Tokyo, Japan). No second samples were available
for con¢rmatory tests.
Statistical analysis
Sample size: If 2000 patients with culture-provenTB are
noti¢ed in the U.K. each year and we estimate that 10%areHIVinfected, then a sample size of159 has 80%power
(a=0.05) to detect 19% compared to a postulated preva-
lence of10%.
Demographics: The characteristics of patients were
analysed using simple descriptive statistics (percentages
or proportions). Proportions were compared using the
Chi-squared test, or Fisher’s exact test when the num-
bers were small.
RESULTS
Two hundred and sixteen (69%) of 313 patients with AFB
seen in clinical specimens or culturepositivemycobacter-
ial infection had culture-provenTB (Table 1). Fifty-seven
(26%) of these 216 patientswere excluded from the study.
These includedpatientswho died early or remained hos-
pitalised during the study period, patients diagnosed in
LSL but treated outside our South London catchment
area, patients who failed to attend or were not referred
to chest clinic and patients who were di⁄cult to bleed.
The HIV serostatus of 159 (74%) of 216 patients was de-
termined and 21 (13%, 95% CIF8^19%) were found to
be HIV seropositive.
In chest clinics, four (3%) of133 patients with culture-
provenTB had undiagnosed HIV, two were subsequently
diagnosed as part of routine clinical care (Table1).Of the
21patientswithTB andHIV, nine (43%) presentedwithTB
as an ADI,10 (48%) were already attending HIV clinics and
were known to be HIV seropositive and two (9%) contin-
ued to attend chest clinicswith undiagnosedHIV (Table 2).
Seven of the nine presenting withTB as an ADI were vo-
luntarily HIV tested as medical inpatients before referral
to HIV clinics.None of the ten in HIV clinics hadbeen pre-
scribedprimaryTB chemoprophylaxis.
Patients withTB and HIV infection were signi¢cantly
more likely to be aged 35^55 years [12/21 (57%) vs. 38/
138 (28%); P=0.006] compared to those testing HIV ser-
onegative.None of the 25 patients from the Indian Sub-
continent were HIV seropositive [0/21 vs. 25/138 (18%),
P=0.047]. There was no signi¢cant di¡erence between
HIV seropositive and seronegative patients for ¢rst or
recurrent TB infections, sex, country of origin or year
of arrival in theU.K. A higher percentage of ethnic ‘Black
Africans’ andpatients arriving in theU.K. after1995were
HIV seropositive, but these di¡erenceswerenot statisti-
cally signi¢cant (Table 3).
DISCUSSION
Principal ¢ndings
Twenty-one (13%, 95% CIF8^19%) of 159 patients diag-
nosed with culture-proven TB were infected with HIV.
Four (3%) of133 patients with culture-provenTB at ¢rst
presentation to chest clinic had HIV. Two remained un-
diagnosed and it is possible they were o¡ered HIV test-
TABLE 1. HIV serostatus of patientswith culture-provenTB entered into study
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HIV presented withTB as an ADI. Patients withTB and
HIV were signi¢cantly more likely to be aged 35^55
years and less likely to be from the Indian Subcontinent.
Strengths of study
To avoid ascertainment bias only patients with culture-
provenTBwere recruited into this study. Inclusion of pa-tients on the basis of smear positivity alone would have
resulted in 79 extra patients with mycobacteria other
than M. tuberculosis (MOTT). Although not all patients
withTB are culture positive, the use of automated liquid
MB/BacT culture systems increased the sensitivity of cul-
ture, in particular, of extra-pulmonary samples (7).
Of the 216 patients with culture-provenTB, 57 (26%)
were excluded from the study. There was no signi¢cant
di¡erence for ¢rst or recurrent infection, age range,
sex, site of disease, country of origin, year of arrival and
TABLE 2. Presentation and diagnosis of patients dually infectedwithTB and HIV
Totalnumberof patientswith culture-provenTB testing HIV seropositive 21/159 (13%)
21patients with culture-provenTB and HIV
HIVundiagnosed in patients attending chest clinics 2/21 (9%)
PresentationwithTB as an AIDS de¢ning illness 9/21 (43%)
Voluntarily HIV tested in chest clinics 2/21 (9%)
Voluntarily HIV tested outside chestclinics and referred to HIV clinics 7/21 (34%)
PresentationwithTB in patients already attendingHIV clinics 10/21 (48%)
PrimaryTB chemoprophylaxis 0
NoprimaryTB chemoprophylaxis 10/10 (100%)
TABLE 3. Demographic, clinical andmicrobiological data onpatientswith culture positiveTB andknownHIV serostatus
HIV positive HIVnegative P-value
Total 21/159 (13%) 138/159 (87%)
Infection
First 20/21 (95%) 129/138 (93%)
Recurrent 1/21 (5%) 9/138 (7%)
Agerange
16^34 7/21 (33%) 73/138 (53%) 1.0a
35^55 12/21 (57%) 38/138 (28%)
455 2/21 (10%) 27/138 (19%)
Sex
Male 12/21 (57%) 83/138 (60%) 0.036a
Female 9/21 (43%) 55/138 (40%)
0.794
Ethnicity
White 5/21 (23%) 31/138 (22%)
Indian Subcontinent 0 25/138 (18%)
Black African 14/21 (67%) 62/138 (45%)
Other 2/21 (10%) 20/138 (15%)
Countryof origin
U.K. 3/21 (14%) 36/138 (26%) 0.086a
Outside U.K. 18/21 (86%) 102/138 (74%)
Yearof arrival
1995 12/18 (67%) 51/102 (50%) 0.290a
1990^5 3/18 (17%) 19/102 (19%)
o1990 2/18 (11%) 31/102 (30%)
Notknown 1/18 (5%) 1/102 (1%)
0.144a
aFisher’s exacttest.Other proportionswere comparedusing Pearson’s chi-squared test.
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cluded from the study.
Passive consent was obtained for HIV testing of left-
over blood by displaying a poster in the chest clinic.This
method of consentminimised the potential for selection
bias as no one refused blood tests. Access to virological
andmicrobiological databases andnotes in chest andHIV
clinics enabledus to calculate notonly a co-infection rate
but also the proportion of patients who presented with
TB as an ADI.
The study was conductedin an area of highTB andHIV
prevalence.Ourconclusions are applicable to other areaswithin theU.K.where theproportion ofpatientswithTB
and undiagnosed HIVat ¢rst presentation to chest clinic
is likely to be less.
Limitations of study
Only demographic data on patients attending chest
clinics were prospectively collected.Data on patients at-
tending HIV clinics were collected retrospectively and
recall and recording bias may have a¡ected the quality
of this data. Amongst the 57 patients excluded, three
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ison to patients who survived, one might expect that
these threeweremore likely to beHIVinfected although
clinically this was not apparent.
Previous prospective studies in London
Two other prospective cohort studies have been con-
ducted at London hospitals. In one smaller study, blood
samples were taken from patients 2 weeks after the in-
itiation of anti-TB therapy and leftover blood was anon-
ymised and tested for HIV. The detectable rate of HIV
amongst patients with culture-provenTBwas16 (23.5%)
out of 68.Thirty-seven out of 39 patients were detected
by voluntary testing, suggesting that o¡ers of HIV test-
ing to patients withTB are largely taken up by those at
risk of HIV infection (8).
A larger study in Southwest London, adjacent to LSL,
estimated that the rate of HIV and TB co-infection was
11.4% (9). Although this study also involved patients with
culture-proven TB there were important di¡erences in
themanner thatpatientswere recruited.The Southwest
studyrecruitedpatients fromTB contact, chest and ‘new
entrant’clinicswhereaswerecruitedpatients fromchest
and HIV clinics. When patients with TB attending non-
HIV clinics are compared, the proportion of patients
withTB and undiagnosed HIV is signi¢cantly di¡erent [4/
133 (3%), LSL vs. 23/202 (11.4%), Southwest London
(P=0.006)].This di¡erencemightbe explainedby thewill-
ingness of non-HIV physicians in LSL to o¡erHIV tests to
patients with suspected TB at ¢rst presentation and, if
seropositive, to refer to HIV clinics.Therewas no statis-
tical di¡erence between patients presenting withTB as
an ADI [9/159 (5.7%), LSL vs. 23/202 (11.4%), Southwest
London] and we failed to ¢nd dual infection among any
patients born in Southern Asia [0/25, LSL vs. 12/97
(12.4%), Southwest study].
Strategies for detecting undiagnosedHIV
associatedwithTB
Within our study the awareness that TB can present as
an ADI is partly a consequence of the reportingmethod
of smear positive or culturepositive results. Amicrobiol-
ogist telephoned results to physicians, and demographic,
clinical and radiological information was obtained for
each case. Physicians were asked to consider HIV testing
depending upon perceived risk (age, ethnicity, sexuality,
intravenous drug use, place of origin, date of arrival in
theU.K. and site of disease).Laboratories have an impor-
tant role in increasing awareness of TB as an ADI, and a
standard comment attached to laboratory reports such
as ‘TB occurs more commonly in immunocompromised
patients’may help to reduce the number of undiagnosed
HIV infections.Should all patients with suspected tuberculosis be
counselled and o¡ered HIV testing in London by April
2002 as recommended by the LondonTB Group and Re-
gionalO⁄ce (10)? The advantage of this strategy is that it
provides an opportunity to diagnose all patients withTB
and HIV.HIV seropositive patients could then be o¡ered
prophylaxis against opportunistic infections andHAART
capable of suppressing viral loads and improving prog-
nosis.However, this and other London-based studies de-
monstrate that thegreatmajorityof patientswithTB are
not infected with HIV. Patients may feel further stigma-
tised by routine HIV testing (11,12) and be less inclined to
attend clinic and take medication regularly, resulting in
more treatment failures andmore drug-resistant TB (13).
Our study shows that themajority of patients withTB
and HIVaccept voluntary testing and are diagnosed out-
side chest clinics. In general, we have a low threshold for
recommending HIV testing to patients withTB.We have
demonstrated that patients with TB do not have the
same risk for HIV (e.g. elderly patients and patients from
the Indian Subcontinent) andbelieve that there shouldbe
exceptions to universal HIV testing. Provided labora-
tories and public health physicians continue to raise
awareness of the association between TB and HIV and
non-HIV physicians remain willing to o¡er HIV testing
to ‘at-risk’ patients, few patients with culture-provenTB
will remain undiagnosed. Repeated prospective anon-
ymised studies HIV testing patients with TB are, how-
ever, essential to ensure this remains the case.
The role of primaryTB chemoprophylaxis
In our study,TB in approximately 50% of patientswithTB
and HIVmight have been prevented by primaryTB che-
moprophylaxis. Prospective randomised control trials
from thepre-HAARTera have demonstrated the bene¢t
of isoniazid prophylaxis in HIV-1 infected patients (14,15).
Primary TB chemoprophylaxis is not currently recom-
mended in BritishThoracic Society (BTS) guidelines (16)
as HAART remains the most important option in any
country with access to anti-retroviral drugs. However,
it is possible that chemoprophylaxis may have a role in
preventing activeTB and in the post-HAARTera further
studies are required.
CONCLUSION
The rate of culture-provenTB and HIV co-infectivity in a
South London community of highTB and HIV prevalence
was 13%. The study also identi¢ed a group of patients
most likely to be infected withTB and HIV.Themajority
of patientswithTB andHIVaccepted voluntary HIV test-
ing andwere diagnosed outside of chest clinics.Less than
2% of patients with TB when discharged from chest
clinics had undiagnosed HIV. At the present time, when
172 RESPIRATORYMEDICINEapproximately 500 newcases ofHIVarenoti¢edannually
in LSL, universal HIV testing in chest clinics is unlikely to
signi¢cantly reduce the number of patients with undiag-
nosed HIV.
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